Latest Biotech News

The FDA moved to approve Replimune’s oncolytic viral therapy, Tudriqev (targeting melanoma), after the program had previously faced an FDA rejection and advisory committee scrutiny. The...

Multiple oncology updates highlighted how new molecular targeting is converging with precision trial design. Otsuka’s Voyxact (anti-APRIL) posted Phase III kidney-function slope data that suggests...

A large long-term study reported that dexrazoxane can protect children’s hearts from lasting chemotherapy damage years after treatment. The findings extend beyond immediate cardiotoxicity...

A bipartisan Senate hearing pressed lawmakers to balance national security goals with incentives for antimicrobial innovation, centering discussions on antimicrobial resistance (AMR) and U.S....

Companies and research groups pushed forward both diagnostic innovation and execution speed. Illumina launched the MiSeq i100 Series-CN in China, locally manufactured for the domestic market, amid...

A cluster of capital-market moves underscored continued investor appetite for biotech, particularly in larger, near-term commercialization paths. Latigo Biotherapeutics priced an IPO at roughly...

The spatial genomics market saw intensified competitive pressure through litigation. Spatial Genomics and Caltech sued 10x Genomics in Delaware, alleging infringement involving five Xenium-related...

Dana-Farber Cancer Institute researchers unveiled a platform to systematically discover molecular glues that redirect E3 ligases toward previously “undruggable” proteins. The approach targets the...

OneOncology said it will embed OpenEvidence’s AI chatbot and search engine into its community oncology clinics to support physician decision-making and literature access. The workflow includes...

Ebola vaccine work reported progress toward broader protection across multiple filovirus species. Researchers described a nanoparticle pan-Ebolavirus vaccine that protected rodents against lethal...

Replimune’s oncolytic viral therapy Tudriqev (Tudriqev) won FDA accelerated approval for advanced melanoma, following a fast, high-stakes regulatory turnaround after the program was previously...

Otsuka’s Voyxact (anti-APRIL) moved the IgA nephropathy conversation again, with phase 3 eGFR-slope data suggesting the anti-APRIL monoclonal antibody could halt or reverse kidney function...

Two biotechs—Latigo Biotherapeutics and Blossomhill Therapeutics—capitalized on a stronger IPO tape, each pushing past expectations in recent debuts. Latigo’s non-opioid, Nav1.8-focused pipeline...

OneOncology said it will embed OpenEvidence’s medical AI chatbot and search engine into community oncology clinics to assist with decision-making and literature navigation. OpenEvidence’s platform...

Takeda’s selective OX2R agonist oveporexton (TAK-861) gained FDA approval as Orzeyful, topping two Phase 3 trials in narcolepsy type 1. The approval makes oveporexton the first approved OX2R...

A new review in Portal Hypertension & Cirrhosis argues that portal hypertension detection is moving toward less invasive approaches by combining imaging, blood-based biomarkers, clinical scoring...

A new blood test approach aims to speed lymphoma diagnosis in resource-limited regions, targeting delays that occur when symptoms overlap with infections, immune disorders, and other conditions....

10x Genomics disclosed that Spatial Genomics and Caltech filed a patent infringement lawsuit over the company’s Xenium spatial biology platform. The case, filed in the U.S. District Court for the...

Researchers at Stanford and the Arc Institute used large language models trained on phage genomes to generate entirely new bacteriophage genomes, reporting that 16 viable phages killed...

IPS Heart’s ISX9-CPC received FDA rare pediatric drug designation for cardiomyopathies associated with dystrophinopathies. The move recognizes the program’s relevance to a subset of pediatric...